{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:08:52Z","timestamp":1788314932600,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["107-2314-B-006-018-, 107-2320-B-006-019-, 108-2320-B-006-023-, 109-2314-B-006 -034 -MY3"],"award-info":[{"award-number":["107-2314-B-006-018-, 107-2320-B-006-019-, 108-2320-B-006-023-, 109-2314-B-006 -034 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["20180254, 20190160"],"award-info":[{"award-number":["20180254, 20190160"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007750","name":"National Cheng Kung University","doi-asserted-by":"publisher","award":["D106-35A13, D107-F2519, NCKUH-10709001"],"award-info":[{"award-number":["D106-35A13, D107-F2519, NCKUH-10709001"]}],"id":[{"id":"10.13039\/501100007750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vigabatrin (VGB) is an approved non-traditional antiepileptic drug that has been revealed to have potential for treating brain tumors; however, its effect on ionic channels in glioma cells remains largely unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>With the aid of patch-clamp technology, we investigated the effects of VGB on various ionic currents in the glioblastoma multiforme cell line 13\u201306-MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In cell-attached configuration, VGB concentration-dependently reduced the activity of intermediate-conductance Ca\n                      <jats:sup>2+<\/jats:sup>\n                      -activated K\n                      <jats:sup>+<\/jats:sup>\n                      (IK\n                      <jats:sub>Ca<\/jats:sub>\n                      ) channels, while DCEBIO (5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one) counteracted the VGB-induced inhibition of IK\n                      <jats:sub>Ca<\/jats:sub>\n                      channels. However, the activity of neither large-conductance Ca\n                      <jats:sup>2+<\/jats:sup>\n                      -activated (BK\n                      <jats:sub>Ca<\/jats:sub>\n                      ) nor inwardly rectifying K\n                      <jats:sup>+<\/jats:sup>\n                      (K\n                      <jats:sub>IR<\/jats:sub>\n                      ) channels were affected by the presence of VGB in human 13\u201306-MG cells. However, in the continued presence of VGB, the addition of GAL-021 or BaCl\n                      <jats:sub>2<\/jats:sub>\n                      effectively suppressed BK\n                      <jats:sub>Ca<\/jats:sub>\n                      and K\n                      <jats:sub>IR<\/jats:sub>\n                      channels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The inhibitory effect of VGB on IK\n                      <jats:sub>Ca<\/jats:sub>\n                      channels demonstrated in the current study could be an important underlying mechanism of VGB-induced antineoplastic (e.g., anti-glioma) actions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-021-00472-3","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T13:03:16Z","timestamp":1610542996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Depressive effectiveness of vigabatrin (\u03b3-vinyl-GABA), an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in human glioma cells"],"prefix":"10.1186","volume":"22","author":[{"given":"Te-Yu","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Ying Ingrid","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-2187","authenticated-orcid":false,"given":"Chin-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"472_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(04)17400-X","volume":"364","author":"AL Lux","year":"2004","unstructured":"Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP. The United Kingdom infantile spasms study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364:1773\u20138.","journal-title":"Lancet"},{"key":"472_CR2","volume":"4","author":"EC Hancock","year":"2008","unstructured":"Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2008;4:CD001770.","journal-title":"Cochrane Database Syst Rev"},{"key":"472_CR3","volume":"3","author":"K Hemming","year":"2008","unstructured":"Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2008;3:CD007302.","journal-title":"Cochrane Database Syst Rev"},{"key":"472_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2165\/00003495-199141060-00007","volume":"41","author":"SM Grant","year":"1991","unstructured":"Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991;41:889\u2013926.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"472_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2125.1989.tb03456.x","volume":"27","author":"PJ Schechter","year":"1989","unstructured":"Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol. 1989;27(Suppl 1):19\u201322.","journal-title":"Br J Clin Pharmacol"},{"key":"472_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.brainres.2007.09.043","volume":"1185","author":"DS Kim","year":"2007","unstructured":"Kim DS, Kim JE, Kwak SE, Choi HC, Song HK, Kimg YI, Choi SY, Kang TC. Up-regulated astroglial TWIK-related acid-sensitive K+ channel-1 (TASK-1) in the hippocampus of seizure-sensitive gerbils: a target of anti-epileptic drugs. Brain Res. 2007;1185:346\u201358.","journal-title":"Brain Res"},{"key":"472_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2174\/092986707780831186","volume":"14","author":"H Wulff","year":"2007","unstructured":"Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14:1437\u201357.","journal-title":"Curr Med Chem"},{"key":"472_CR8","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/onc.2009.25","volume":"28","author":"H Lallet-Daher","year":"2009","unstructured":"Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackiere F, Bidaux G, Urbain R, Gosset P, Delcourt P, Fleurisse L, Slomianny C, Dewailly E, Mauroy B, Bonnal JL, Skryma R, Prevarskaya N. Intermediate-conductance ca2+\u2212activated k+ channels (ikca1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. 2009;28:1792\u2013806.","journal-title":"Oncogene"},{"key":"472_CR9","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1113\/jphysiol.2011.219378","volume":"589","author":"Z Liang","year":"2011","unstructured":"Liang Z, Chen L, McClafferty H, Lukowski R, MacGregor D, King JT, Rizzi S, Sausbier M, McCobb DP, Knaus HG, Ruth P, Shipston MJ. Control of hypothalamic-pituitary-adrenal stress axis activity by the intermediate conductance calcium-activated potassium channel, SK4. J Physiol. 2011;589:5965\u201386.","journal-title":"J Physiol"},{"key":"472_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1124\/jpet.111.182782","volume":"338","author":"S Ohya","year":"2011","unstructured":"Ohya S, Niwa S, Kojima Y, Sasaki S, Sakuragi M, Kohri K, Imaizumi Y. Intermediate-conductance Ca2+- activated K+ channel, KCa3.1, as a novel therapeutic target for benign prostatic hyperplasia. J Pharmacol Exp Ther. 2011;338:528\u201336.","journal-title":"J Pharmacol Exp Ther"},{"key":"472_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1152\/physrev.00018.2011","volume":"92","author":"A Schwab","year":"2012","unstructured":"Schwab A, Fabian A, Hanley PJ, Stock C. Role of ion channels and transporters in cell migration. Physiol Rev. 2012;92:1865\u2013913.","journal-title":"Physiol Rev"},{"key":"472_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2174\/13816128113199990032","volume":"20","author":"L Leanza","year":"2014","unstructured":"Leanza L, O'Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, Szabo I. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Curr Pharm Des. 2014;20:189\u2013200.","journal-title":"Curr Pharm Des"},{"key":"472_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2174\/1389450013348173","volume":"2","author":"BS Jensen","year":"2001","unstructured":"Jensen BS, Str\u00f8baek D, Olesen SP, Christophersen P. The Ca2+-activated K+ channel of intermediate conductance: a molecular target for novel treatments? Curr Drug Targets. 2001;2:401\u201322.","journal-title":"Curr Drug Targets"},{"key":"472_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nn.3990","volume":"18","author":"M Zonouzi","year":"2015","unstructured":"Zonouzi M, Scafidi J, Li P, McEllin B, Edwards J, Dupree JL, Harvey L, Sun D, H\u00fcbner CA, Cull-Candy SG, Farrant M, Gallo V. GABAergic regulation of cerebellar NG2 cell development is altered in perinatal white matter injury. Nat Neurosci. 2015;18:674\u201382.","journal-title":"Nat Neurosci"},{"key":"472_CR15","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1158\/0008-5472.CAN-16-2289","volume":"77","author":"PM Schnepp","year":"2017","unstructured":"Schnepp PM, Lee DD, Guldner IH, O'Tighearnaigh TK, Howe EN, Palakurthi B, Eckert KE, Toni TA, Ashfeld BL, Zhang S. GAD1 upregulation programs aggressive features of cancer cell metabolism in the brain metastatic microenvironment. Cancer Res. 2017;77:2844\u201356.","journal-title":"Cancer Res"},{"key":"472_CR16","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1007\/s12035-018-1457-2","volume":"56","author":"TY Hung","year":"2019","unstructured":"Hung TY, Chu FL, Wu DC, Wu SN, Huang CW. The Protective Role of Peroxisome Proliferator-Activated Receptor-Gamma in Seizure and Neuronal Excitotoxicity. Mol Neurobiol. 2019;56:5497\u2013506.","journal-title":"Mol Neurobiol"},{"key":"472_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biom9100638","volume":"9","author":"MC Lai","year":"2019","unstructured":"Lai MC, Tzeng RC, Huang CW, Wu SN. The Novel Direct Modulatory Effects of Perampanel, an Antagonist of AMPA Receptors, on Voltage-Gated Sodium and M-type Potassium Currents. Biomolecules. 2019;9:E638.","journal-title":"Biomolecules"},{"key":"472_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/ALN.0000000000000367","volume":"121","author":"M Roozekrans","year":"2014","unstructured":"Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology. 2014;121:459\u201368.","journal-title":"Anesthesiology"},{"key":"472_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000341449","volume":"30","author":"CL Wang","year":"2013","unstructured":"Wang CL, Tsai ML, Wu SN. Evidence for mitoxantrone-induced block of inwardly rectifying K+ channels expressed in the osteoclast precursor RAW 264.7 cells differentiated with lipopolysaccharide. Cell Physiol Biochem. 2013;30:687\u2013701.","journal-title":"Cell Physiol Biochem"},{"key":"472_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","volume":"127","author":"CY Lee","year":"2016","unstructured":"Lee CY, Lai HY, Chiu A, Chan SH, Hsiao LP, Lee ST. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol. 2016;127:445\u201353.","journal-title":"J Neurooncol"},{"key":"472_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00424-014-1523-1","volume":"467","author":"RW Turner","year":"2015","unstructured":"Turner RW, Kruskic M, Teves M, Scheidl-Yee T, Hameed S, Zamponi GW. Neuronal expression of the intermediate conductance calcium-activated potassium channel kca3.1 in the mammalian central nervous system. Pflugers Arch. 2015;467:311\u201328.","journal-title":"Pflugers Arch"},{"key":"472_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173482","volume":"887","author":"TY Hung","year":"2020","unstructured":"Hung TY, Huang CW, Wu SN. High ability of zileuton ((\u00b1)-1-(1-benzo [b]thien-2-ylethyl)-1-hydroxyurea) to stimulate I K(Ca) but suppress I K(DR) and I K(M) independently of 5-lipoxygenase inhibition. Eur J Pharmacol. 2020;887:173482.","journal-title":"Eur J Pharmacol"},{"key":"472_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/jnnp-2014-308136","volume":"86","author":"JA Koekkoek","year":"2015","unstructured":"Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ. Seizure reduction in a low-grade glioma: More than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry. 2015;86:366\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"472_CR24","volume-title":"Clinical Challenges in Therapeutic Drug Monitoring","author":"GA McMillin","year":"2016","unstructured":"McMillin GA, Krasowski MD. Therapeutic Drug Monitoring of Newer Antiepileptic Drugs. In: Clinical Challenges in Therapeutic Drug Monitoring; 2016."},{"key":"472_CR25","doi-asserted-by":"crossref","unstructured":"Silverman RB. The organic chemistry of drug design and drug action. In: Chapter 5. Enzyme inhibition and inactivation. 2nd ed. Burlington: Elsevier; 2004. p. 290.","DOI":"10.1016\/B978-0-08-051337-9.50010-9"},{"key":"472_CR26","doi-asserted-by":"publisher","first-page":"C1070","DOI":"10.1152\/ajpcell.00040.2012","volume":"303","author":"MB McFerrin","year":"2012","unstructured":"McFerrin MB, Turner KL, Cuddapah VA, Sontheimer H. Differential role of IK and BK potassium channels as mediators of intrinsic and extrinsic apoptotic cell death. Am J Physiol Cell Physiol. 2012;303:C1070\u20138.","journal-title":"Am J Physiol Cell Physiol"},{"key":"472_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0070-2161(08)60941-7","volume-title":"Potassium ion channels: molecular structure, function, and diseases. Current Topics in Membranes","author":"Y Horie","year":"1999","unstructured":"Horie Y, Kurachi Y. Glial inwardly rectifying potassium channels. In: Kurachi Y, Jan LY, Lazdunski M, editors. Potassium ion channels: molecular structure, function, and diseases. Current Topics in Membranes, vol. 46. San Diego: Academic; 1999. p. 471\u201382."},{"key":"472_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00021.2009","volume":"90","author":"H Hibino","year":"2010","unstructured":"Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev. 2010;90:291\u2013366.","journal-title":"Physiol Rev"},{"key":"472_CR29","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1159\/000443112","volume":"38","author":"PS Yeh","year":"2016","unstructured":"Yeh PS, Wu SJ, Hung TY, Huang YM, Hsu CW, Sze CI, Hsieh YJ, Huang CW, Wu SN. Evidence for the Inhibition by temozolomide, an imidazotetrazine family alkylator, of intermediate-conductance Ca2+-activated K+ channels in glioma cells. Cell Physiol Biochem. 2016;38:1727\u201342.","journal-title":"Cell Physiol Biochem"},{"key":"472_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.radonc.2011.05.069","volume":"101","author":"M Steinle","year":"2011","unstructured":"Steinle M, Palme D, Misovic M, Rudner J, Dittmann K, Lukowski R, Ruth P, Huber SM. Ionizing radiation induces migration of glioblastoma cells by activating BK K(+) channels. Radiother Oncol. 2011;101:122\u20136.","journal-title":"Radiother Oncol"},{"key":"472_CR31","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/cancers11091285","volume":"11","author":"CJ Mohr","year":"2019","unstructured":"Mohr CJ, Gross D, Sezgin EC, Steudel FA, Huber RO, SM LR. KCa 3.1 channels confer radioresistance to breast cancer cells. Cancers (Basel). 2019;11:1285.","journal-title":"Cancers (Basel)"},{"key":"472_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/cancers11010109","volume":"11","author":"CJ Mohr","year":"2019","unstructured":"Mohr CJ, Steudel FA, Gross D, Ruth P, Lo WY, Hoppe R, Schroth W, Brauch H, Huber SM, Lukowski R. Cancer-associated intermediate conductance ca (2+)-activated k+ channel k (ca)3.1. Cancers (Basel). 2019;11:109.","journal-title":"Cancers (Basel)"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00472-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-021-00472-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00472-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T13:41:02Z","timestamp":1610545262000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-021-00472-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1186\/s40360-021-00472-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-25157\/v5","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25157\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25157\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25157\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25157\/v4","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study did not involve human participants and animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}